Florian Rabiller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florian Rabiller has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Aarno Palotie
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications Alejandra Freire-Regatillo
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
2 shared publications- Alfredo Ramirez
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
2 shared publications Anne-Marie Ayral
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
2 shared publicationsAudrey Coulon
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Lille, France
2 shared publications- Avishek Roy
Department of Physiology All India Institute for Medical Sciences New Delhi India
2 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2164-2176
PLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures
- 14 August 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (9) , 2164-2176
Open AccessPLCG2 downregulation impairs synaptic function and increases Alzheimer’s disease hallmarks in neuronal cultures
- Open Access
- 31 May 2024
- Published by Springer Nature in Research Square
Neuronal downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease hallmarks
We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may impair synaptic mechanisms in rat primary neuronal cultures. Out of the gene targets identified, we found that shRNA-mediated downregulation of Plcg2 in mouse dentate gyrus neurons consistently impaired dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and was associated with increased levels of Aβ and Tau phosphorylation, potentially via the AKT/GSK3β axis. Very rare PLCG2 loss-of-functon(LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLCγ2 levels, consistent with nonsense-mediated mRNA decay mechanisms. Restoring PLCγ2 levels in shPLCG2-hNCs fully reversed the disease-related phenotypes. Our findings indicate that the downregulation of PLCγ2 increases the risk of AD by impairing synaptic function and increasing the levels of Aβ and Tau phosphorylation in neurons.
- 31 May 2024
- Published by Springer Nature in Research Square
Open AccessNeuronal downregulation of PLCG2 impairs synaptic function and elicits Alzheimer disease hallmarks
We developed a high content screening to investigate how Alzheimer disease (AD) genetic risk factors may impair synaptic mechanisms in rat primary neuronal cultures. Out of the gene targets identified, we found that shRNA-mediated downregulation of Plcg2 in mouse dentate gyrus neurons consistently impaired dendritic morphology and synaptic function. In human neuronal cultures (hNCs), PLCG2 downregulation also impaired synaptic function and was associated with increased levels of Aβ and Tau phosphorylation, potentially via the AKT/GSK3β axis. Very rare PLCG2 loss-of-functon(LoF) variants were associated with a 10-fold increased AD risk. PLCG2 LoF carriers exhibit low mRNA/protein PLCG2/PLCγ2 levels, consistent with nonsense-mediated mRNA decay mechanisms. Restoring PLCγ2 levels in shPLCG2-hNCs fully reversed the disease-related phenotypes. Our findings indicate that the downregulation of PLCγ2 increases the risk of AD by impairing synaptic function and increasing the levels of Aβ and Tau phosphorylation in neurons.